Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 6 | BMC Immunology

Fig. 6

From: CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients

Fig. 6

CD16 low expression on neutrophils predicted pro-tumor immune status in CRC patients with capecitabine therapy. Peripheral venous blood from CRC patients received single-agent oral capecitabine adjuvant therapy was collected 6–9 months after the therapy and analyzed for different immune cell subsets by flow cytometry. CD16 MFI of peripheral blood neutrophils was calculated by flow cytometry analysis, and the correlations between CD16 MFI of neutrophils and frequencies of CD8+ T cells (a), CD4+ T cells (b), monocytes (c), NK cells (d), cDCs (e) and pDCs (f) among total peripheral blood leukocytes were analyzed by Pearson’s correlation test

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us